Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature ...
Incyte (NASDAQ:INCY) executives outlined the company’s near-term launch priorities and mid-stage pipeline plans during a ...
Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a ...
An innovative care delivery model at Mayo Clinic integrates virtual oversight, remote patient monitoring, mobile health ...
In this video, Paolo Tarantino, MD, PhD, an advanced fellow at Dana-Farber Cancer Institute, discusses the “need and appeal” for oncology education to contextualize “emerging and evolving data in ...
Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results